Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Research & Development: 2016-2024

Historic Research & Development for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to $71.9 million.

  • Cidara Therapeutics' Research & Development rose 185.86% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.8 million, marking a year-over-year increase of 299.27%. This contributed to the annual value of $71.9 million for FY2024, which is 95.52% up from last year.
  • According to the latest figures from FY2024, Cidara Therapeutics' Research & Development is $71.9 million, which was up 95.52% from $36.8 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Research & Development peaked at $77.4 million during FY2022, and registered a low of $36.8 million during FY2023.
  • Moreover, its 3-year median value for Research & Development was $71.9 million (2024), whereas its average is $62.0 million.
  • In the last 5 years, Cidara Therapeutics' Research & Development plummeted by 52.51% in 2023 and then surged by 95.52% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Research & Development (Yearly) stood at $68.0 million in 2020, then climbed by 7.45% to $73.1 million in 2021, then rose by 5.91% to $77.4 million in 2022, then crashed by 52.51% to $36.8 million in 2023, then spiked by 95.52% to $71.9 million in 2024.